FIELD: medicine, psychiatry, neurology.
SUBSTANCE: the present innovation deals with treating affected amnestic functions in women after uterine and adnexal extirpation. For this purpose, after a 7-d-long introduction of estradiol as suppositories at curative dosage of 8-20 mcg/kg body weight patients should be additionally injected with galanthamine intramuscularly once daily for 7-10 d at the dosage 5 mg, moreover, decreasing the number of estradiol injections up to once/3 d. The innovation suggested provides high antiamnestic effect at decreased dosage of preparations due to their agonistic action.
EFFECT: higher efficiency of therapy.
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS FOR CORRECTION OF CHOLINERGIC DISORDERS OF THE MNESTIC PROCESSES | 2017 |
|
RU2665970C1 |
| AGENT SHOWING PROPERTIES OF COGNITIVE FUNCTION ACTIVATOR (VERSIONS) | 2010 |
|
RU2438672C1 |
| ACTIVE INGREDIENT OF MEDICINAL AGENT WITH CEREBROPROTECTIVE, ANTIHYPOXIC AND ANTIAMNESTIC ACTIVITY FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND METHOD FOR PREPARING THE SAME | 2023 |
|
RU2821508C1 |
| OXALATE N,N-DIMETHYL-2-N,N-DIMETHYLAMINOMETHYLPYRIDYL-3-CARBAMATE, POSSESSING ANTI-CHOLINESTERASE ACTIVITY AND ABILITY TO IMPROVE COGNITIVE FUNCTIONS | 2007 |
|
RU2339620C1 |
| PEPTIDE FOR TREATMENT OF ALZHEIMER'S DISEASE | 2017 |
|
RU2678987C2 |
| N,N'-SUBSTITUTED 3,7-DIAZABICYCLO[3.3.1]NONANES, PHARMACEUTICAL COMPOSITIONS BASED THEREON AND USE THEREOF | 2015 |
|
RU2613071C1 |
| NEUROPROTECTOR | 2004 |
|
RU2268715C1 |
| NEUROTROPIC AGENT WITH ANTIOXIDANT, ANTIHYPOXIC, NEUROPROTECTOR, ANTIAMNESIC AND ANTI-MOTION SICKNESS ACTIVITY AND CAPABLE OF ENHANCING COGNITIVE FUNCTIONS | 2008 |
|
RU2394816C1 |
| THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE AND METHOD OF TREATING ALZHEIMER'S DISEASE | 2011 |
|
RU2536232C2 |
| PHARMACEUTICALLY ACCEPTABLE ACETYL-(D-LYS)-LYS-ARG-ARG-AMIDE PEPTIDE SALTS | 2021 |
|
RU2763136C1 |
